Ionis Pharmaceuticals Inc. (IONS) Business Metric Overview - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Ionis Pharmaceuticals Inc...

    NASDAQ: IONS · Real-Time Price · USD
    59.35
    -1.14 (-1.88%)
    At close: Sep 04, 2025, 3:59 PM

    Ionis Pharmaceuticals Revenue Breakdown

    Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
    Collaborative Agreement Revenue Revenue 45.03M 146.24M 44.88M 141.52M 179.14M 44.17M 91.01M 38.33M 49.94M 69.25M 38.25M 49.78M 87.27M 84.82M 85.86M 84.45M 95.66M 95.34M 89.73M 83.96M 95.7M 88.3M 68.09M 82.76M 57.2M 42.02M
    Collaborative Agreement Revenue Revenue Growth -69.21% +225.82% -68.29% -21.00% +305.60% -51.47% +137.42% -23.24% -27.88% +81.06% -23.17% -42.95% +2.88% -1.21% +1.67% -11.72% +0.34% +6.25% +6.88% -12.27% +8.38% +29.68% -17.72% +44.68% +36.11% n/a
    Commercial Revenue 76.17M 145.31M 75.73M 72.04M 78.84M 84.08M 77.9M 67.77M 80.48M 72.41M 78.18M 72.28M 39.98M 15.52M n/a n/a n/a n/a n/a 66.01M 81.67M 70.5M 59.71M 70.01M 56.65M 41.08M
    Commercial Revenue Growth -47.58% +91.88% +5.13% -8.64% -6.23% +7.94% +14.95% -15.79% +11.14% -7.39% +8.16% +80.80% +157.63% n/a n/a n/a n/a n/a n/a -19.18% +15.84% +18.07% -14.71% +23.58% +37.91% n/a
    Other Commercial Revenue 5.71M 32.12M 13.15M 11.51M 34.5M 16.83M 16.89M 62.76M 71.41M 87.36M 55.61M 69.63M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Other Commercial Revenue Growth -82.20% +144.18% +14.25% -66.63% +105.01% -0.34% -73.09% -12.12% -18.25% +57.10% -20.14% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Product Sales, Net Revenue 6.29M 200.76M 58.08M 153.21M 245.66M 60.13M 110.51M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Product Sales, Net Revenue Growth -96.87% +245.65% -62.09% -37.63% +308.58% -45.59% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Research and Development Revenue Revenue 55.44M 102.14M 57.21M 56.74M 112.11M 67.25M 61.01M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Research and Development Revenue Revenue Growth -45.72% +78.54% +0.82% -49.39% +66.70% +10.23% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Royalty Revenue 64.17M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Royalty Revenue Growth n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    SPINRAZA Royalties Revenue 48.01M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    SPINRAZA Royalties Revenue Growth n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    TEGSEDI and WAYLIVRA Revenue 5.71M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    TEGSEDI and WAYLIVRA Revenue Growth n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

    Operating Expense Breakdown

    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
    Selling, General, and Administrative Revenue 90.6M 76.25M 88.1M 61.6M 59.53M 46.99M 71M 70M 46M 46M 47.9M 34.4M 33.8M 34.1M 38M 30.1M 45.1M 57.1M 139M 68.45M 72.02M 74.99M 83M 60.04M 76M 68.22M 67.1M 68.71M 66.2M 43.65M 45.71M 26.79M 22.32M 13.68M 18.04M 10.19M 9.82M 10.56M 13.18M 8.75M 7.78M 7.47M
    Selling, General, and Administrative Revenue Growth +18.82% -13.45% +43.02% +3.47% +26.69% -33.81% +1.43% +52.17% 0.00% -3.97% +39.24% +1.78% -0.88% -10.26% +26.25% -33.26% -21.02% -58.92% +103.08% -4.95% -3.97% -9.65% +38.25% -21.01% +11.40% +1.67% -2.34% +3.80% +51.65% -4.49% +70.62% +20.03% +63.17% -24.20% +77.10% +3.71% -6.99% -19.87% +50.62% +12.55% +4.14% n/a
    Research and Development Revenue 217.46M 200.76M 245.49M 219.76M 222.06M 214.22M 256.56M 215M 230M 198M 308M 182.99M 180.76M 161.13M 179M 184.77M 139.31M 139.8M 171M 125.08M 122.26M 116.95M 149M 104.37M 106M 106.42M 113.45M 95.25M 101.83M 104.07M 128.28M 80.21M 83.51M 82.64M 101.15M 84.63M 77.57M 80.96M 101.33M 88.51M 68.01M 64.45M
    Research and Development Revenue Growth +8.32% -18.22% +11.71% -1.04% +3.66% -16.50% +19.33% -6.52% +16.16% -35.71% +68.32% +1.23% +12.18% -9.99% -3.12% +32.64% -0.35% -18.25% +36.71% +2.31% +4.54% -21.51% +42.77% -1.54% -0.39% -6.20% +19.10% -6.46% -2.15% -18.88% +59.93% -3.94% +1.05% -18.30% +19.52% +9.10% -4.19% -20.10% +14.49% +30.15% +5.52% n/a

    Add to Watchlist